AstraZeneca PLC (AZN)
162.49
+0.02
(+0.01%)
USD |
NYSE |
Sep 02, 12:42
AstraZeneca Research and Development Expense (Annual) : 13.84B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 13.84B |
| December 31, 2024 | 12.22B |
| December 31, 2023 | 10.34B |
| December 31, 2022 | 9.639B |
| December 31, 2021 | 8.547B |
| December 31, 2020 | 6.094B |
| December 31, 2019 | 5.32B |
| December 31, 2018 | 5.266B |
| December 31, 2017 | 5.412B |
| December 31, 2016 | 5.631B |
| December 31, 2015 | 5.594B |
| December 31, 2014 | 4.941B |
| December 31, 2013 | 4.230B |
| December 31, 2012 | 4.263B |
| December 31, 2011 | 4.500B |
| December 31, 2010 | 4.098B |
| December 31, 2009 | 4.216B |
| December 31, 2008 | 4.878B |
| Date | Value |
|---|---|
| December 31, 2007 | 5.089B |
| December 31, 2006 | 3.885B |
| December 31, 2005 | 3.379B |
| December 31, 2004 | 3.475B |
| December 31, 2003 | 3.451B |
| December 31, 2002 | 3.069B |
| December 31, 2001 | 2.687B |
| December 31, 2000 | 2.62B |
| December 31, 1999 | 1.704B |
| December 31, 1998 | 1.173B |
| December 31, 1997 | 1.069B |
| December 31, 1996 | 939.22M |
| December 31, 1995 | 866.42M |
| December 31, 1994 | 793.01M |
| December 31, 1993 | 735.70M |
| December 31, 1992 | 761.82M |
| December 31, 1991 | 662.98M |
| December 31, 1990 | 648.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| GSK Plc | 8.171B |
| Johnson & Johnson | 14.83B |
| Eli Lilly & Co. | 13.34B |
| Merck & Co., Inc. | 12.51B |
| Novo Nordisk A/S | 6.838B |